Rui Shang - Publications

Global knockout of VEGFB improves lipoprotein lipase activity leading to an improved lipid profile during diabetes.

Journal: Frontiers in pharmacology

Published: December 03, 2025

The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors.

Journal: Cell metabolism

Published: September 18, 2025

Cardioprotective effects of a 'twincretin' drug tirzepatide in heart failure following myocardial infarction.

Journal: Cardiovascular research

Published: February 04, 2025

Lipoprotein lipase as a target for obesity/diabetes related cardiovascular disease.

Journal: Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques

Published: April 28, 2024

Heparanase Stimulation of Physiologic Cardiac Hypertrophy Is Suppressed After Chronic Diabetes, Resulting in Cardiac Remodeling and Dysfunction.

Journal: Diabetes

Published: March 15, 2024

Reduction in Insulin Uncovers a Novel Effect of VEGFB on Cardiac Substrate Utilization.

Journal: Arteriosclerosis, thrombosis, and vascular biology

Published: December 27, 2023

Flow-Induced Secretion of Endothelial Heparanase Regulates Cardiac Lipoprotein Lipase and Changes Following Diabetes.

Journal: Journal of the American Heart Association

Published: November 23, 2022

Cardiac-specific VEGFB overexpression reduces lipoprotein lipase activity and improves insulin action in rat heart.

Journal: American journal of physiology. Endocrinology and metabolism

Published: November 08, 2021

Lipoprotein Lipase and Its Delivery of Fatty Acids to the Heart.

Journal: Biomolecules

Published: June 05, 2021

Involvement of Heparanase in Endothelial Cell-Cardiomyocyte Crosstalk.

Journal: Advances in experimental medicine and biology

Published: April 11, 2020